

SAMPLE UB-04 CLAIM FORM



MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

1-888-461-2255

For Product Administered in the
Hospital Outpatient Setting—
Effective 09/01/09

1 PATIENT NAME		2 PATIENT ADDRESS		3 PATIENT CITY/STATE/ZIP		4 PATIENT PHONE		5 PAT. ENCL. #		6 TYPE OF BILL	
7 OCCURRENCE DATE		8 OCCURRENCE DATE		9 OCCURRENCE DATE		10 OCCURRENCE DATE		11 OCCURRENCE DATE		12 OCCURRENCE DATE	
13 DRUGS/DETAIL CODES		14 HCPCS / RATE / MPPS CODE		15 SERV. UNITS		16 TOTAL CHARGES		17 NON-COVERED CHARGES		18	
19		20		21		22		23		24	
25		26		27		28		29		30	
31		32		33		34		35		36	
37		38		39		40		41		42	
43		44		45		46		47		48	
49		50		51		52		53		54	
55		56		57		58		59		60	
61		62		63		64		65		66	
67		68		69		70		71		72	
73		74		75		76		77		78	
79		80		81		82		83		84	
85		86		87		88		89		90	
91		92		93		94		95		96	
97		98		99		100		101		102	

A **Field 42 & 43:**
Enter the appropriate revenue codes & descriptions corresponding to HCPCS codes in Field 44 - e.g.:

212 - Level I Nervous System Injections
636 - Drugs/Detail Codes
760 & 761 - Treatment Room

B **Field 44:**
Enter the appropriate HCPCS and CPT codes.

- MYOBLOC - J0587, Botulinum Toxin Type B (per 100 Units)
- Injection - 64613, Chemodestruction of muscle(s); cervical spinal muscles(s). Other diagnosis codes may be appropriate.

C **Field 46:**
Enter the number of billing units. For J0587, a billing Unit is per 100 Units of MYOBLOC.

Please note that not all claims processing systems allow three digits in this field. In these cases Units administered that are equal to or greater than 10,000 may need to be broken down on multiples lines, (e.g., 99 and 1 for 10,000 Units or 99, 98, and 3 for 20,000 Units).

D **Fields 56, 76-79:**
National Provider Identifier (NPI).

Field 56: Enter NPI for the Facility
Field 76: Enter NPI for the Attending Physician
Field 77: Enter NPI for the Operating Physician
Field 78 and 79: Enter NPI for Other Provider Type

E **Fields 67-75:**
Enter the appropriate ICD-9-CM diagnosis code, e.g., 333.83 (spasmodic torticollis). Other diagnosis codes may be acceptable. Please note that field 67 is for the principal diagnosis and fields 68-75 are for secondary diagnoses if necessary.

F **Field 80:**
Some payers may require that NDC numbers be entered into the electronic comment field. If required, the NDC numbers are entered with a "0" in the 6th position. See below:

- 10454-0710-10 MYOBLOC 2,500 Units/mL
- 10454-0711-10 MYOBLOC 5,000 Units/mL
- 10454-0712-10 MYOBLOC 10,000 Units/mL

The above diagnosis and procedure codes are provided as examples only. The healthcare provider is responsible for determining the appropriate codes for an individual patient.

See boxed warning and Important Safety Information on reverse side. Also see accompanying full Prescribing Information.

Service & Support

1-888-461-2255

8:00 AM - 7:00 PM Eastern Time Monday-Friday

Reimbursement • Ordering • Information

www.myobloc.com

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information).

Important Safety Information

Myobloc® (rimabotulinumtoxinB) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Before administering MYOBLOC, physicians should consult the full Prescribing Information and Medication Guide. Note to representatives: Please provide full Prescribing Information and Medication Guide when presenting this material.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.



MYOBLOC®

rimabotulinumtoxinB
Injection [5,000 Units/mL]

Service & Support

For more information about our Reimbursement Services and Patient Assistance Programs, or to obtain application forms, please call **1-888-461-2255** or visit our Web site at **www.myobloc-reimbursement.com**

SOLSTICE™
NEUROSCIENCES

www.solsticeneuro.com

© 2009 Solstice Neurosciences, Inc.

Myobloc® is a registered trademark of Solstice Neurosciences, Inc.

SNI-MYO397-0809